We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+21.61%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$3.64B
AUM Growth
-$358M
Cap. Flow
-$561M
Cap. Flow %
-15.41%
Top 10 Hldgs %
62.29%
Holding
72
New
2
Increased
4
Reduced
13
Closed
10

Top Buys

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$77M
2
TYRA icon
Tyra Biosciences
TYRA
+$31.5M
3
ALLK
Allakos
ALLK
+$12.4M
4
IMUX icon
Immunic
IMUX
+$11.6M
5
UNCY icon
Unicycive Therapeutics
UNCY
+$1.81M

Top Sells

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$158M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$69.8M
3
MRUS
Merus
MRUS
+$64.1M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$54.1M
5
KURA icon
Kura Oncology
KURA
+$50.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
1
MoonLake Immunotherapeutics
MLTX
$1.59B
$1.09B 30.04%
21,751,284
– –
KYMR icon
2
Kymera Therapeutics
KYMR
$8.6B
$208M 5.7%
5,161,801
– –
RVMD icon
3
Revolution Medicines
RVMD
$39.9B
$193M 5.3%
5,981,212
– –
FDMT icon
4
4D Molecular Therapeutics
FDMT
$539M
$125M 3.44%
3,922,413
-85,000
-2% -$2.17M
GHRS icon
5
GH Research
GHRS
$1.95B
$111M 3.05%
10,400,158
– –
JANX icon
6
Janux Therapeutics
JANX
$931M
$110M 3.02%
2,919,818
-1,660,000
-36% -$36.2M
MIRM icon
7
Mirum Pharmaceuticals
MIRM
$6.66B
$110M 3.02%
4,370,024
– –
PTGX icon
8
Protagonist Therapeutics
PTGX
$8.7B
$109M 2.99%
3,755,990
-1,988,858
-35% -$54.1M
IONS icon
9
Ionis Pharmaceuticals
IONS
$8.61B
$105M 2.89%
2,428,613
– –
OLMA icon
10
Olema Pharmaceuticals
OLMA
$1.02B
$103M 2.84%
9,135,893
– –
KURA icon
11
Kura Oncology
KURA
$805M
$102M 2.81%
4,786,293
-2,586,935
-35% -$50.3M
XOMA
12
DELISTED
Xoma
XOMA
$87.4M 2.4%
3,633,743
– –
CGON icon
13
CG Oncology
CGON
$6.27B
$82.7M 2.27%
+1,884,191
New +$77M
TYRA icon
14
Tyra Biosciences
TYRA
$1.91B
$76.4M 2.1%
4,661,194
+1,921,599
+70% +$31.5M
EPIX
15
DELISTED
ESSA Pharma
EPIX
$74.3M 2.04%
8,748,629
– –
ZYME icon
16
Zymeworks
ZYME
$1.63B
$61.8M 1.7%
5,870,000
– –
LKFT
17
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.79B
$60M 1.65%
1,863,809
-51,300
-3% -$1.91M
CGEM icon
18
Cullinan Oncology
CGEM
$1.03B
$54.5M 1.5%
3,196,701
– –
MRUS
19
DELISTED
Merus
MRUS
$52.8M 1.45%
1,172,249
-1,580,171
-57% -$64.1M
IDYA icon
20
IDEAYA Biosciences
IDYA
$3.46B
$51M 1.4%
1,162,306
-566,737
-33% -$24.4M
ANNX icon
21
Annexon
ANNX
$839M
$50.2M 1.38%
7,000,000
– –
RPTX
22
DELISTED
Repare Therapeutics
RPTX
$48.7M 1.34%
10,333,600
– –
ETNB
23
DELISTED
89bio
ETNB
$47.1M 1.3%
4,047,354
– –
SNDX icon
24
Syndax Pharmaceuticals
SNDX
$1.69B
$44.6M 1.23%
1,875,000
– –
ACIU icon
25
AC Immune
ACIU
$226M
$43.1M 1.19%
14,571,236
– –
1
2 3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2024 Portfolio in Review

As of Q1 2024, BVF Inc held 72 positions worth $3.64B, down 9% from $4B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

BVF Inc withdrew a net $561M in Q1 2024, closing 10 positions and reducing 13 holdings. Its most notable exit was Axsome Therapeutics, an estimated $158M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, BVF Inc opened a new position in CG Oncology worth $82.7M.

  • BVF Inc's largest Q1 2024 buy was CG Oncology: 1,884,191 shares worth $82.7M.
  • BVF Inc added most to Tyra Biosciences in Q1 2024, an estimated $31.5M increase.
  • BVF Inc's biggest Q1 2024 reduction was Merus, cutting an estimated $64.1M.
  • BVF Inc fully exited Axsome Therapeutics in Q1 2024, selling an estimated $158M.
  • BVF Inc's ten largest holdings make up 62% of its $3.64B portfolio in Q1 2024.
  • BVF Inc opened 2 new positions and closed 10 in Q1 2024.
  • BVF Inc's portfolio value fell 9% quarter-over-quarter to $3.64B.

Based on BVF Inc's 13F filing for Q1 2024, filed 15 May 2024.